Park JJ, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1–8.

Article  PubMed  Google Scholar 

Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.

Article  CAS  PubMed  Google Scholar 

Park JW, Minetta C, Liu D, Yee C, Yau, Laura J, Van’t Veer W, Fraser Symmans M, Paoloni, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim ES, Roy S, Herbst, Ignacio I, Wistuba JJ, Lee GR, Blumenschein A Jr, Tsao DJ, Stewart et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer discovery 1, no. 1 (2011): 44–53.

Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin Trails. 2013;10(5):720–34.

Article  Google Scholar 

Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trails. 2018;15(2):149–58.

Article  Google Scholar 

Neuenschwander B, Wandel S, Roychoudhury S, Bailey S. Robust exchangeability designs for early phase clinical trials with multiple strata. Pharm Stat. 2016;15(2):123–34.

Article  PubMed  Google Scholar 

Lyu J, Zhou T, Yuan S, Guo W, Ji Y. MUCE: Bayesian hierarchical modelling for the design and analysis of phase 1b multiple expansion cohort trials. J Royal Stat Soc Ser C: Appl Stat. 2023;72(3):649–69.

Article  Google Scholar 

Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trails. 2024;21(3):273–86.

Article  Google Scholar 

Lin R, Zhou Y, Yan F, et al. BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol. 2020;16:1392–402.

Google Scholar 

Zhou Y, Lee J, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019;38:5299–316.

Article  PubMed  PubMed Central  Google Scholar 

Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004;60(3):684–93.

Article  PubMed  Google Scholar 

Jin IH, Liu S, Thall PF, et al. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc. 2014;109(506):525–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang P, Li D, Lin R, Huang B, Yuan Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Stat Med. 2024;43(15):2972–86.

Article  PubMed  Google Scholar 

Qiu Y, Li M. (2025). A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials. Pharm Stat, 24(2), e2451.

Jiang Z, Mi G, Lin J, Lorenzato C, Ji Y. A multi-arm two-stage (MATS) design for proof-of-concept and dose optimization in early-phase oncology trials. Contemp Clin Trials. 2023;132:107278.

Article  PubMed  Google Scholar 

Wang S, Peter F, Thall K, Takeda, Yuan Y. ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics 80, no. 4 (2024): ujae105.

Fu C, Zhou S, Jack Lee J. Posterior Predictive Design for Phase I Clinical Trials. J Am Stat Assoc (2025): 1–12.

Qiu Y, Li M. A robust Bayesian dose optimization design with backfill and randomization for phase I/II clinical trials. Stat Methods Med Res (2025): 09622802251374290.

Messer K, et al. A novel, efficient and seamless Phase 2A-2B design to test varoglutamstat in early AD: the VIVA‐MIND study. Alzheimer’s Dement. 2022;18:e065197.

Article  Google Scholar 

Di Stefano F, Rodrigues C, Galtier S, et al. Incorporation of Healthy Volunteers Data on Receptor Occupancy into a Phase II Proof-of-Concept Trial Using a Bayesian Dynamic Borrowing Design. Biom J. 2023;65:8: 2200305.

Article  Google Scholar 

Edwards D, Best N, Crawford J, Zi L, Shelton C, Fowler A. Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study. Therapeutic Innov Regul Sci. 2024;58(1):1–10.

Article  Google Scholar 

Krotka P, Posch M, Gewily M, Höglinger G, Roig B, M. (2025). Statistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non-Concurrent Controls. Biom J, 67(3), e70059.

Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian Time Machine: Accounting for Temporal Drfit in Multi-Arm Platform Trials. Clin Trails. 2022;19:5: 490–501.

Article  Google Scholar